Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A randomized, double-blind, placebo-controlled phase 3 study: Efficacy and safety of recombinant BCG VPM1002 in reducing SARS-CoV-2 infection rate and COVID-19 severity
Type of trial Phase III
Trial ID NCT 04439045
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for front-line employees of provincial or municipal police force who do not have COVID-19. Study participants will receive VPM1002 (BCG vaccine) or placebo to see if the vaccine prevents COVID-19 infection or reduces its severity.

Study team
Princess Margaret Cancer Centre
.
.
Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT 04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

Study team
Donald Arnold
Dr. Donald Arnold
MD
McMaster University
Trial name A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia
Type of trial Pending
Trial ID NCT 04331665
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for people with COVID-19 who need supplemental oxygen because of COVID-19. All study participants will get ruxolitinib to see if it prevents them from needing machines to help with breathing or needing more supplemental oxygen.

Study team
Dr. Steven Chan
Dr. Steven Chan
MD, PhD
Princess Margaret Cancer Centre
Dr. Vikas Gupta
Dr. Vikas Gupta
MD
Princess Margaret Cancer Centre
Trial name A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)
Type of trial Phase III
Trial ID NCT 04320615
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario
Trial description

This study compares tocilizumab with placebo in people who are hospitalized with severe COVID-19 to see if tocilizumab improves clinical symptoms.

Study team
Hoffmann-La Roche Limited
.
.
Trial name An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19
Type of trial Phase III
Trial ID NCT 04327388
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Ontario, British Columbia
Trial description

This study is for people who are hospitalized with severe or critical COVID-19 infection. The study compares sarilumab and placebo to see if sarilumab prevents death and impoves clinical symptoms of COVID-19.

Study team
Trial name An Investigation on the Effects of Icosapent Ethyl (Vascepa™) on Inflammatory Biomarkers in Individuals with COVID-19 Cardiolink-9
Type of trial Phase II
Trial ID NCT 04412018
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for people with COVID-19 who are not hospitalized. Study participants will either (1) take icosapent ethyl, or (2) receive usual care. The study is to see if icosapent ethyl improves the results of blood tests related to COVID-19.

Study team
Dr. Subodh Verma
Dr. Subodh Verma
MD, PhD
Canadian Medical and Surgical Knowledge Translation Research Group
Trial name Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Type of trial Phase III
Trial ID NCT 04324463
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This is two studies for people with COVID-19, one for people who are not hospitalized, and one for people who are hospitalized. The study is to compare combinations of azithromycin, hydroxychloroquine or chloroquine, and interferon-beta to usual care. For people who are not hospitalized, the study is to see if the study drugs prevent hospitalization. For people who are hospitalized, the study is to see the study drugs prevent severe symptoms of COVID-19 or death.

Study team
Richard Whitlock
Richard Whitlock
MD, PhD
Population Health Research Institute
Emilie Belley-Cote
Emilie Belley-Cote
MD, PhD
Population Health Research Institute
Trial name Cellular Immunotherapy for COVID-19 acute respiratory distress syndrome (ARDS)
Type of trial Phase I
Trial ID NCT 04400032
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This is a study for adults hospitalized with COVID-19 who need a machine to help them breathe. Study participants will receive mesenchymal stroma cells to see if the treatment is safe to use in humans, and to determine the maximum dose that can be safely used.

Study team
Dr. Duncan Stewart
Dr. Duncan Stewart
MD
The Ottawa Hospital
Trial name Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
Type of trial Phase III
Trial ID NCT 04362085
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This study is for people who are hospitalized for COVID-19. The study compares therapeutic anticoagulation (low molecular weight heparin or unfractionated heparin) with standard care to see if therapeutic anticoagulation reduces intensive care unit admissions, reduces the need for machines to help with breathing, and/or prevents death.

Study team
Dr. Michelle Sholzberg
Dr. Michelle Sholzberg
MD FRCPC
St.Michael's Hospital, Toronto
Dr. Peter Jüni
Dr. Peter Jüni
MD FESC
St. Michael's Hospital, Toronto
Dr. Mary Cushman
Dr. Mary Cushman
MD
University of Vermont Medical Center, Vermont
Trial name CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children
Type of trial Phase II
Trial ID NCT04377568
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Trial description

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

Study team
Dr. Julia Upton
Dr. Julia Upton
MD, MPH, Study Chair
Allergy and Immunology Department, The Hospital for Sick Children
Trial name Control of COVID-19 outbreak in long term care
Type of trial Phase II
Trial ID No Id
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for adults living in long term care homes. Study participants receive favipiravir or placebo to see if favipiravir prevents COVID-19 outbreaks.

Study team
Dr. Alison McGeer
Dr. Alison McGeer
Senior Clinician Scientist
Lunenfeld-Tanenbaum Research Institute, Mount Sinai, Toronto ON
Trial name COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir (CORIPREV-LR)
Type of trial Phase III
Trial ID NCT 04321174
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, British Columbia
Trial description

This study is for people who have been in close contact with someone who has COVID-19. The study is to see if lopinavir/ritonavir can prevent COVID-19 from being transmitted.

Study team
Dr. Darrell Tan
Dr. Darrell Tan
MD, FRCPC, PhD
St. Michael’s Hospital
Trial name Exogenous Surfactant Administration for Patients with COVID-19
Type of trial Phase I | Phase II
Trial ID NCT04375735
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for people who are hospitalized with COVID-19 who need a machine to help with breathing. Study participants will receive either (1) Bovine Lipid Extract Surfactant (BLES), or (2) standard treatment. The study is to see if BLES is safe to use and to see if BLES prevents death.

Study team
Dr. Jim Lewis
Dr. Jim Lewis
MD
Lawson Health Research Institute
Trial name Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection
Type of trial Not Applicable
Trial ID NCT 04323761
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This study is to provide expanded access to remdesivir for people who are hospitalized with COVID-19.

Study team
Gilead Clinical Study Information Center
Gilead Study Director
Gilead Study Director
William Osler Health System
Brampton, Ontario, Canada, L6R 3J7
William Osler Health System
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
The Ottawa Hospital
Trial name Interferon Lambda for Immediate Antiviral therapy at Diagnosis (ILIAD): A phase II randomized, open-label, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19
Type of trial Phase II
Trial ID NCT 04354259
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This study is for people who have COVID-19 and either hospitalized or not hospitalized. The study compares Peginterferon Lambda-1A (an injected drug) and placebo to see if people who get Peginterferon Lambda-1A recover from COVID-19, and to see if they will recover faster.

 

Study team
Jordan Feld
Dr. Jordan Feld
MD
University Health Network, Toronto
Trial name Post-exposure Prophylaxis (PEP) or Preemptive Therapy for COVID-19: A Pragmatic Randomized Clinical Trial
Type of trial Phase III
Trial ID NCT 04308668
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Manitoba, Alberta, Ontario
Trial description

This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.

Study team
Todd C. Lee
Todd C. Lee, MD, MPH, FIDSA
Associate Professor in the Department of Medicine
McGill University
Ryan Zarychanski
Ryan Zarychanski
MD
University of Manitoba
Lauren E. Kelly
Lauren E. Kelly, PhD, MSc, CCRP
Clinical Trialist and Certified Clinical Research Professional with SoCRA
Organization
IIan Schwartz
IIan Schwartz
MD
University of Alberta
Emily McDonald
Emily McDonald, MD, MSc, FRCPC
Assistant Professor of Medicine
Organization
Dr. Zain Chagla
Dr. Zain Chagla
MD MSc FRCPC DTMH
McMaster University
Trial name Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada
Type of trial Phase III
Trial ID NCT 04374942
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario
Trial description

This study is for health care workers in the emergency department who are exposed to patients with COVID-19. The study compares hydroxychloroquine with placebo to see whether it prevents COVID-19. 

Study team
Dr. Megan Landes
Dr. Megan Landes
Clinical Investigator
Toronto General Hospital Research Institute (TGHRI)
Dr. Kevin Kain
Dr. Kevin Kain
MD
University Health Network, Toronto
Trial name Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)
Type of trial Phase IV
Trial ID NCT 02735707
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Quebec
Trial description

This study is for people who are hospitalized in the intensive care unit for COVID-19. The study measures whether different treatments and combinations of treatments will prevent death.

Study team
Dr. John Marshall
Dr. John Marshall
MD
Director, Critical Care Research, St. Michael’s Hospital, Unity Health
Dr. Deborah Cook
Dr. Deborah Cook
MD
St. Joseph's Healthcare Hamilton
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke
Trial name Safety and Efficacy of Post-Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in Institutions
Type of trial Phase III
Trial ID NCT 04397328
Health Canada Status Health Canada approved
Trial Status Pending
Location
Ontario
Trial description

This study is for people who are living in an institute (rehabilitation, long term care facility, mental health facility, or veteran's care) who are at high-risk of complications and have been exposed to someone with COVID-19. Study participants will take hydroxychloroquine or placebo. The study is to see if hydroxychloroquine prevents COVID-19.

Study team
Michael Borrie
Michael Borrie
MB, ChB
Lawson Health Research Institute
Trial name Therapeutic-dose anti-coagulation for the treatment of hospitalized patients with COVID-19: the antthrombotic therapy to ameliorate complications of COVID01 (ATTACC) trial
Type of trial Phase II | Phase III
Trial ID NCT04372589
Health Canada Status Health Canada approved
Trial Status Open
Location
British Columbia, Manitoba, Ontario, Quebec, Saskatchewan
Trial description

This study is for people who are hospitalized for COVID-19. Study participants will receive heparin or usual care, to see if heparin prevents the need for a machine to help with breathing or death.

Study team
Dr. Patrick Lawler
Dr. Patrick Lawler
MD, MPH
Peter Munk Cardiac Centre/University Health Network
Dr. Ewan Goligher
Dr. Ewan Goligher
MD, PhD
University Health Network, Toronto
Dr. Ryan Zarychanski
Dr. Ryan Zarychanski
MD, MSc, FRCPC
University of Manitoba
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Health Canada approved
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec
Trial description

This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.

Study team
Dr. Nelson Lee
Dr. Nelson Lee
MD
University of Alberta Hospital
Dr. Allison Mah
Dr. Allison Mah
MD
Vancouver General Hospital,
Dr. Natasha Press
Dr. Natasha Press
MD
St. Paul’s Hospital
Dr. Shane English
Dr. Shane English
MD
The Ottawa Hospital
Dr. Robert Fowler
Dr. Robert Fowler
MD
Sunnybrook Health Sciences Centre
Dr. Bryan Coburn
Dr. Bryan Coburn
MD
Toronto Western Hospital
Dr. Matthew Cheng
Dr. Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Dr. Alexis Turgeon
Dr. Alexis Turgeon
MD
CHU de Québec – Université Laval
Dr. Francois Lellouche
Dr. Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
Dr. Daniel Ovekim
Dr. Daniel Ovekim
MD
Royal Jubilee Hospital
Dr. Anna Geagea
Dr. Anna Geagea
MD
North York General Hospital
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke